YAP1 and Friedreich ataxia: To assess the consequence of YAP1 or BIRC2-3 inhibition on the viability of FA-HNSCCs with 11q22.2 amplifications, dose–response assays using AZD5582, a potent inhibitor of BIRC2-4, and CA3, an inhibitor of the YAP1-TEAD interaction were performed (Fig. 5d, Supplementary Fig. 5A).